公开(公告)号：US20220387486A1

公开(公告)日：2022-12-08

申请号：US17246351

申请日：2021-04-30

申请人： Novartis AG ,  The Trustees of the University of Pennsylvania

发明人： Barbara Brannetti ,  Jennifer Brogdon ,  Boris Engels ,  Brian Walter Granda ,  Lu Huang ,  Ming Lei ,  Na Li ,  Jimin Zhang ,  Carla Patricia Pinto Guimaraes ,  Saar Gill ,  Marco Ruella ,  Regina M. Young

IPC分类号： A61K35/17 ,  C07K16/28 ,  A61P35/00 ,  A61K38/17 ,  C12N15/85

摘要： The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.

公开(公告)号：US11413340B2

公开(公告)日：2022-08-16

申请号：US16065387

申请日：2016-12-21

申请人： Novartis AG ,  The Trustees of the University of Pennsylvania ,  DANA-FARBER CANCER INSTITUTE, INC. ,  PRESIDENT AND FELLOWS OF HARVARD COLLEGE

发明人： Jennifer Brogdon ,  Hwai Wen Chang ,  Boris Engels ,  Gordon James Freeman ,  Gerhard Johann Frey ,  Jennifer Marie Mataraza ,  Reshma Singh ,  Arlene Helen Sharpe

IPC分类号： A61K39/395 ,  A61K39/00 ,  A61P35/00 ,  A61K45/06

摘要： Provided are compositions for use in methods for treating diseases associated with expression of mesothelin comprising administering a cell that expresses a chimeric antigen receptor (CAR) specific to mesothelin in combination with a PD-L1 inhibitor.

公开(公告)号：US20210087279A1

公开(公告)日：2021-03-25

申请号：US16941148

申请日：2020-07-28

申请人： Novartis AG ,  The Trustees of the University of Pennsylvania

发明人： Boris Engels ,  Andreas Loew ,  Michael C. Milone ,  Li Zhou

IPC分类号： C07K16/28 ,  C07K14/725 ,  A61K38/00 ,  C07K14/705 ,  C07K16/00 ,  A61K39/00 ,  A61K38/17 ,  A61K39/395 ,  C12N15/62

摘要： Provided are compositions and methods relating to regulatable chimeric antigen receptors (RCARs), natural killer cell receptor CARs (NKR-CARs), and regulatable NKR-CARs (RNKR-CARs), where the intracellular signaling or proliferation of the RCAR or RNKR-CAR can be controlled to optimize the use of an RCAR/NKR-CAR- or RNKR-CAR-expressing cell to provide an immune response. Cells can be engineered to express a RNKR-CAR or to express a RCAR and a NKR-CAR (e.g., inhibitory NKR-CAR). For example, a RCAR or RNKR-CAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR or RNKR-CAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.

公开(公告)号：US10577417B2

公开(公告)日：2020-03-03

申请号：US15511973

申请日：2015-09-17

申请人： Novartis AG ,  The Trustees of the University of Pennsylvania

发明人： Gregory Beatty ,  Boris Engels ,  Neeraja Idamakanti ,  Carl H. June ,  Andreas Loew ,  Michael C. Milone ,  Huijuan Song ,  Enxiu Wang ,  Qilong Wu

IPC分类号： A61K35/17 ,  C07K14/705 ,  C07K16/28 ,  C07K16/30 ,  C07K14/725 ,  C07K14/74 ,  C12N5/0783

摘要： The present invention provides compositions and methods for regulating the specificity and activity of immune effector cells for use in immunotherapy. In one embodiment, the invention provides a type of chimeric antigen receptor (CAR) wherein the CAR is termed a “NKR-CAR” which is a CAR design comprising a component of a receptor naturally found on natural killer (NK) cells. In one embodiment, the NK receptor includes but is not limited to a naturally occurring activating and inhibitory receptor of NK cells known as a killer cell immunoglobulin-like receptor (KIR).

公开(公告)号：US10525083B2

公开(公告)日：2020-01-07

申请号：US15727402

申请日：2017-10-06

申请人： Novartis AG ,  The Trustees of the University of Pennsylvania

发明人： Barbara Brannetti ,  Jennifer Brogdon ,  Boris Engels ,  Brian Granda ,  Lu Huang ,  Ming Lei ,  Na Li ,  Jimin Zhang ,  Carla Guimaraes

IPC分类号： A61K35/17 ,  A61P35/00 ,  A61K38/17 ,  C12N15/85 ,  C07K16/28 ,  A61K39/00

摘要： The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.

公开(公告)号：US11981731B2

公开(公告)日：2024-05-14

申请号：US16743772

申请日：2020-01-15

申请人： Novartis AG ,  The Trustees of the University of Pennsylvania

发明人： Gregory Beatty ,  Boris Engels ,  Neeraja Idamakanti ,  Carl H. June ,  Andreas Loew ,  Michael C. Milone ,  Huijuan Song ,  Enxiu Wang ,  Qilong Wu

IPC分类号： A61K35/17 ,  C07K14/705 ,  C07K14/725 ,  C07K14/735 ,  C07K14/74 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783

CPC分类号： C07K16/28 ,  A61K35/17 ,  C07K14/705 ,  C07K14/70503 ,  C07K14/7051 ,  C07K14/70535 ,  C07K14/70539 ,  C07K14/7056 ,  C07K14/70596 ,  C07K16/30 ,  C12N5/0636 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/74 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/70 ,  C07K2319/74 ,  C12N2510/00

摘要： The present invention provides compositions and methods for regulating the specificity and activity of immune effector cells for use in immunotherapy. In one embodiment, the invention provides a type of chimeric antigen receptor (CAR) wherein the CAR is termed a “NKR-CAR” which is a CAR design comprising a component of a receptor naturally found on natural killer (NK) cells. In one embodiment, the NK receptor includes but is not limited to a naturally occurring activating and inhibitory receptor of NK cells known as a killer cell immunoglobulin-like receptor (KIR).

公开(公告)号：USRE49847E1

公开(公告)日：2024-02-27

申请号：US17569389

申请日：2022-01-05

申请人： Novartis AG ,  The Trustees of the University of Pennsylvania

发明人： Barbara Brannetti ,  Jennifer Brogdon ,  Boris Engels ,  Brian Granda ,  Lu Huang ,  Ming Lei ,  Na Li ,  Jimin Zhang ,  Carla Guimaraes ,  Saar Gill ,  Marco Ruella ,  Regina M. Young

IPC分类号： A61K35/17 ,  A61K38/17 ,  C07K16/28 ,  C12N15/85 ,  A61P35/00 ,  A61K39/00

CPC分类号： A61K35/17 ,  A61K38/1774 ,  A61P35/00 ,  C07K16/2803 ,  C07K16/2887 ,  C07K16/2896 ,  C12N15/85 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/622 ,  C07K2319/03 ,  C07K2319/33

摘要： The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.

公开(公告)号：US20210177900A1

公开(公告)日：2021-06-17

申请号：US17104961

申请日：2020-11-25

申请人： Novartis AG

发明人： Boris Engels ,  Carla Patricia Guimaraes

IPC分类号： A61K35/17 ,  C07K14/705 ,  C12N5/0783

摘要： The present disclosure provides compositions and methods for treating diseases associated with expression of CD19 and/or CD22, e.g., by administering a recombinant T cell or natural killer (NK) cell comprising a CD22 CAR and a CD19 CAR as described herein. The disclosure also relates to CAR molecules specific to CD22 and/or CD19, methods of making a cell comprising the same and vectors encoding the same.

公开(公告)号：US11026976B2

公开(公告)日：2021-06-08

申请号：US16664223

申请日：2019-10-25

申请人： Novartis AG ,  The Trustees of the University of Pennsylvania

发明人： Barbara Brannetti ,  Jennifer Brogdon ,  Boris Engels ,  Brian Walter Granda ,  Lu Huang ,  Ming Lei ,  Na Li ,  Jimin Zhang ,  Carla Guimaraes ,  Saar Gill ,  Marco Ruella ,  Regina M. Young

IPC分类号： C07K16/28 ,  A61P35/00 ,  A61K38/17 ,  A61K39/00 ,  A61K35/17 ,  C12N15/85

摘要： The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.

公开(公告)号：US20200377589A1

公开(公告)日：2020-12-03

申请号：US16743772

申请日：2020-01-15

申请人： Novartis AG ,  The Trustees of the University of Pennsylvania

发明人： Gregory Beatty ,  Boris Engels ,  Neeraja Idamakanti ,  Carl H. June ,  Andreas Loew ,  Michael C. Milone ,  Huijuan Song ,  Enxiu Wang ,  Qilong Wu

IPC分类号： C07K16/28 ,  C07K16/30 ,  C07K14/735 ,  C07K14/705 ,  A61K35/17 ,  C07K14/725 ,  C07K14/74 ,  C12N5/0783

摘要： The present invention provides compositions and methods for regulating the specificity and activity of immune effector cells for use in immunotherapy. In one embodiment, the invention provides a type of chimeric antigen receptor (CAR) wherein the CAR is termed a “NKR-CAR” which is a CAR design comprising a component of a receptor naturally found on natural killer (NK) cells. In one embodiment, the NK receptor includes but is not limited to a naturally occurring activating and inhibitory receptor of NK cells known as a killer cell immunoglobulin-like receptor (KIR).